Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group, Dose-range-finding Study of Two Delayed Release Formulations of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation

NCT02559206 is registered in ClinicalTrials.gov with Ironwood Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02559206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02559206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group, Dose-range-finding Study of Two Delayed Release Formulations of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 22, 2015
Completion date
September 30, 2016
Enrollment
759 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome with constipation